Latest posts
-
Beyond New Molecules: Why India Must Broaden Its Understanding of Pharmaceutical Innovation
For more than two decades, the conversation on pharmaceutical patents in India has revolved around a familiar set of themes — product patents, Section 3(d) of the Patents Act, evergreening, compulsory licensing, and the…
-
From Regulatory Reform to Global Competitiveness – Where Does Indian Pharma Go from Here?
Executive Summary: On July 30, 2026, Reuters reported that India’s pharmaceutical quality initiative—launched in response to quality concerns that emerged in late 2022—had resulted in regulatory action against…
-
The Age of Accountability: What India’s Pharmaceutical Industry Must Learn from a Public Movement
Recent policy initiatives suggest the Government is responding to changing public expectations. Should the pharmaceutical industry do the same—for the sake of patients? Executive Summary: India is witnessing a profound…
-
The Next Frontier in Healthcare Isn’t Just Better Medicines – It’s Better Decisions
How a recent Government initiative could quietly reshape the future of healthcare, pharmaceutical innovation and patient care in India Executive Summary: On 17 February 2026, the Government of India launched…
-
When a Medicine’s Brand Name Becomes a Patient Safety Issue: What CDSCO’s Draft Proposal Signals for the Future of Indian Pharma
Can a medicine’s brand name save—or endanger—a patient’s life? At first glance, the question seems counterintuitive. Medicines save lives because of their pharmacology, not because of the names printed on their…
-
The New License to Compete: Why Indian Pharma Must Rethink the Rules of Competition
Executive Summary: For more than four decades, Indian pharmaceutical companies have built a formidable global reputation through affordable manufacturing, process innovation, regulatory excellence and an unwavering…
-
Understanding the Multinational Perspective: Legitimate Concerns, but Not the Complete Answer (Part: III)
No discussion on pharmaceutical innovation in India is complete without acknowledging why multinational research-based pharmaceutical companies continue to advocate for stronger intellectual property protection. Viewed…
-
How Does India Compare with Other Pharmaceutical Innovation Leaders? (Part: II)
Two decades after the introduction of product patents, it is reasonable to ask whether India’s intellectual property ecosystem remains a significant barrier to pharmaceutical innovation. The answer, however, is neither…
-
Twenty Years After India’s Product Patent Regime: Why Hasn’t India Produced More Home-Grown New Medicines? (Part: I)
Beyond Patents: What Global Innovation Leaders Teach Us About Building a Pharmaceutical Innovation Ecosystem—and Where India Still Has Ground to Cover Editor’s Note: The relationship between intellectual property and…
-
From Prescription Influence to Healthcare Intelligence: The Next Growth Engine That Could Redefine Indian Pharmaceutical Marketing
The Next Decade Will Not Belong to Those Who Market Medicines Better — But to Those Who Understand Healthcare Better Indian pharmaceutical marketing has reached an interesting inflection point. For more than four…